Sep 8, 2026 · 54 min
China turns biotech strength into strategic leverage
China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge
The episode connects a high-stakes Trump-Xi meeting with a less visible shift in pharmaceutical power that leaves the United States reliant on Chinese supply chains.
- 1China’s expanding institutions, manufacturing base, and diplomatic reach are reshaping its leverage before the Trump-Xi meeting.
- 2Chinese biotech is attracting global licensing deals through faster trials, strong drug pipelines, lower costs, and AI-enabled discovery.
- 3U.S. dependence on Chinese pharmaceutical inputs creates supply-chain vulnerability even as China becomes a source of innovation.
Don't miss
Ruby Wong distinguishes China’s established role as a scaled drug manufacturer from its newer emergence as a biotech and pharmaceutical innovator.
The brief
Ahead of the September Trump-Xi meeting, the discussion asks whether Washington still holds the stronger hand as China expands its influence through trade, diplomacy, and regional institutions.
AI safety emerges as a narrow possible bridge between the two powers: shared risks might permit coordination even without agreement on a broader global regulatory framework.
Ruby Wong, author of China Cure, explains how faster clinical trials, lower development costs, AI-enabled research, and strong scientific teams are drawing multinational licensing deals.
The pharmaceutical relationship is increasingly two-sided: U.S. companies depend on China for active ingredients and antibiotics, while Chinese firms supply promising assets and innovation.
The episode closes by looking ahead to China’s expanding role in global clinical trials and Shanghai’s Star Market as a destination for technology and advanced-manufacturing companies.
Featuring
Donald John Trump
Xi Jinping
China Cure
United StatesBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.